Gyre Therapeutics (GYRE) Shares Outstanding (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Shares Outstanding (Entity) of $91.3 million for Q1 2026, up 4.22% year-over-year from $87.6 million in Q1 2025, and little changed quarter-over-quarter from $91.3 million in Q4 2025.
Gyre Therapeutics (GYRE) Shares Outstanding (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Shares Outstanding (Entity) for 17 consecutive years, with $91.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 4.22% year-over-year to $91.3 million; the TTM figure through Mar 2026 stood at $91.3 million (up 4.22% YoY), while the FY2025 annual figure was $91.3 million, up 5.8% from the prior year.
- Shares Outstanding (Entity) steadied at $91.3 million in Q1 2026 per GYRE's latest filing, from $91.3 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $91.3 million in Q1 2026 and bottomed at $2.1 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $52.2 million across 5 years, with a median of $85.4 million in 2024.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) climbed 0.31% — and 2024, when it surged 3293.25%.
- Gyre Therapeutics' Shares Outstanding (Entity) stood at $2.5 million in 2022, then soared by 2942.85% to $76.6 million in 2023, then climbed by 12.68% to $86.3 million in 2024, then rose by 5.8% to $91.3 million in 2025, then rose by 0.03% to $91.3 million in 2026.
- Business Quant data shows GYRE's Shares Outstanding (Entity) at $91.3 million in Q1 2026, $91.3 million in Q4 2025, and $90.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 100.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 100.64 Mn |
| Mar 31, 2026 | 91.32 Mn |
| Dec 31, 2025 | 89.34 Mn |
| Sep 30, 2025 | 90.85 Mn |
| Jun 30, 2025 | 89.12 Mn |
| Mar 31, 2025 | 86.42 Mn |
| Dec 31, 2024 | 85.09 Mn |
| Sep 30, 2024 | 85.64 Mn |
| Jun 30, 2024 | 85.50 Mn |
| Mar 31, 2024 | 83.27 Mn |
| Dec 31, 2023 | 65.83 Mn |
| Sep 30, 2023 | 2.53 Mn |
| Jun 30, 2023 | 2.52 Mn |
| Mar 31, 2023 | 2.52 Mn |
| Dec 31, 2022 | 2.10 Mn |
| Sep 30, 2022 | 2.10 Mn |
| Jun 30, 2022 | 2.10 Mn |
| Mar 31, 2022 | 2.10 Mn |
| Dec 31, 2021 | 2.04 Mn |
| Sep 30, 2021 | 2.09 Mn |